Oncology

Tumor biology and anticancer therapy: from mechanism papers to pivotal readouts and launches.

662 picksRelatedImmunotherapy Tumor microenvironment ADCs & conjugates

Latest picks

661–662 of 662

Aug 4Tue

Tuesday

00:00
WeChatPickScore7474
Curium to Acquire Radiopharmaceutical Maker Lantheus in $8 Billion Deal
Curium and Lantheus Holdings (NASDAQ:LNTH) have signed a definitive agreement under which Lantheus will merge with a wholly owned subsidiary of Curium US Holdings LLC, in a deal worth $8 billion. Both companies develop and supply radiopharmaceuticals aimed at improving cancer diagnosis and treatment. Completion of the merger is the next step.
Industry #Deals & financing #Oncology
Why it matters: Large merger consolidating two radiopharmaceutical companies in the cancer diagnostics and therapy space.
00:00
WeChatPickScore8282
FDA Approves Novartis Pluvicto for PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer
The US FDA has approved Novartis's Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), roughly doubling the eligible patient population. In the PSMAddition study, Pluvicto plus standard of care (ADT plus ARPI) reduced the risk of disease progression or death by 33% versus standard of care alone, with a positive overall survival trend (HR=0.80). About half of men with mHSPC progress within 20 months.
Regulatory #Regulatory #Oncology #Novartis
Why it matters: FDA label expansion for Pluvicto into earlier-line mHSPC nearly doubles its eligible population.